Clinical trials
Transthyretin Cardiac Amyloidosis clinical trials
Below are recruiting transthyretin cardiac amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07766135Recruiting
Liver and blood clotting in heart amyloidosis
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
Messina, SicilyAges 18 years+ - NCT06978660Recruiting
AI-powered ECG test for early cardiac amyloidosis
This trial tests if an AI can spot early signs of cardiac amyloidosis from a standard 10-second ECG. If successful, it could lead to faster diagnosis and treatment.
Evanston, IllinoisAges 18 years+ - NCT07306949RecruitingPhase 4
Acoramidis for transthyretin cardiac amyloidosis
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
Bunkyō CityAges 18–100 - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT04535349Recruiting
Imaging heart uptake of bone tracer in ATTR amyloidosis
This study uses special imaging tracers to see how much they build up in the heart in people with cardiac transthyretin (ATTR) amyloidosis. It may help researchers better measure disease activity and understand who benefits from treatments like tafamidis.
CaenAges 18–100 - NCT04667494RecruitingPhase 4
Ultrasound treatment for heart amyloidosis
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Boston, MassachusettsAges 18–90 - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT06034405Recruiting
Checking spine tissue for heart amyloidosis signs
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
Beverly Hills, CaliforniaAges 50 years+ - NCT06907836Recruiting
Transthyretin cardiac amyloidosis in internal medicine
This study looks back at medical records of patients who were diagnosed with transthyretin cardiac amyloidosis (a type of protein buildup in the heart) while hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023. It aims to describe their health journey and outcomes.
StrasbourgAges 18 years+ - NCT07314268Recruiting
Study of tiny blood particles in heart amyloidosis
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
São Paulo, São PauloAges 18 years+ - NCT07238426Enrolling by invitation
Heart screening for older adults in Ordu, Turkey
This study is a screening program in Ordu, Turkey, to find older adults (65+) who might have a heart condition called cardiac amyloidosis. It uses medical records and heart ultrasounds to check people who already have certain heart problems.
Ordu, OrduAges 65 years+ - NCT06251778Recruiting
National study of ATTR heart amyloid patients on tafamidis
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
PaviaAges 18–99 - NCT06101108Recruiting
Early heart screening in back surgery patients
This trial checks people having back surgery for spinal stenosis to see if they have an early sign of heart amyloidosis (a protein buildup in the heart). The goal is to find this condition early so it can be treated before it causes problems.
BrugesAges 60 years+ - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT05758493RecruitingPhase 2
Iodine-124 scan study for systemic amyloidosis
This Phase 2 study tests an iodine-based scan medicine to help learn how systemic amyloidosis affects the body and organs. It may help doctors better characterize the disease using specific imaging tests.
Portland, OregonAges 40–90 - NCT05776212Recruiting
Imaging study for certain heart amyloidosis types and heart thickening
This trial uses special heart imaging to better measure how amyloid deposits affect the heart in people with certain diagnoses. The goal is to understand which imaging signals match your disease and to see if this approach could help guide care.
GroningenAges 40 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT06197165Recruiting
Shiatsu for amyloidosis symptoms and quality of life
This study tests whether shiatsu (a gentle Japanese touch therapy) can improve symptoms and quality of life for people with amyloidosis. If you have a bothersome symptom like pain, shortness of breath, or anxiety, this trial may help you feel better.
CréteilAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT06082050RecruitingEarly Phase 1
YOLT-201 for transthyretin heart disease
This trial tests a new intravenous medicine called YOLT-201 for people with a heart condition caused by buildup of a protein called transthyretin (ATTR-CM). The goal is to see if it can slow or improve the disease.
Hangzhou, ZhejiangAges 18–80
Hear when a new Transthyretin Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transthyretin cardiac amyloidosis?
- Yes. Clin2 currently lists 27 recruiting transthyretin cardiac amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transthyretin cardiac amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transthyretin cardiac amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.